Paper20404136
Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia.
Long J and 7 others. Blood, 2010. Cited by 75 papers, by iCite.
Cite this record
ConductScience Library. Multiple distinct molecular mechanisms influence sensitivity and resistance to MDM2 inhibitors in adult acute myelogenous leukemia. Papers, record 20404136. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/20404136
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics28
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Apoptosis | Major topic |
| Drug Resistance, Neoplasm | Major topic |
| Proto-Oncogene Proteins c-mdm2 | Major topic |
| Acute Disease | |
| Adult | |
| Aged | |
| Aged, 80 and over | |
| Cell Cycle Proteins | |
| Cell Line, Tumor | |
| Cells, Cultured | |
| Female | |
| Flow Cytometry | |
| Humans | |
| Imidazoles | |
| Immunoblotting | |
| Indoles | |
| Leukemia, Myeloid | |
| Male | |
| Middle Aged | |
| Nuclear Proteins | |
| Piperazines | |
| Proto-Oncogene Proteins | |
| Reverse Transcriptase Polymerase Chain Reaction | |
| Spiro Compounds | |
| Tumor Cells, Cultured | |
| Tumor Suppressor Protein p53 | |
| Young Adult | |
| fms-Like Tyrosine Kinase 3 |
Source PubMed
Grants6
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| R01 CA136537 | NCI NIH HHS | United States | R01CA136537 | PubMed and NIH | NIH RePORTER |
| P30 CA046592 | NCI NIH HHS | United States | P30CA046592 | PubMed and NIH | NIH RePORTER |
| 1R01 CA136537-01 | NCI NIH HHS | United States | R01CA136537 | PubMed and NIH | NIH RePORTER |
| UL1RR024986 | NCRR NIH HHS | United States | UL1RR024986 | PubMed and NIH | NIH RePORTER |
| 5 P30 CA46592 | NCI NIH HHS | United States | P30CA046592 | PubMed and NIH | NIH RePORTER |
| UL1 RR024986 | NCRR NIH HHS | United States | UL1RR024986 | PubMed and NIH | NIH RePORTER |
References49
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 11867746 | NQO1 stabilizes p53 through a distinct pathway. | Proc Natl Acad Sci U S A | 2002 | https://conductscience.org/library/papers/11867746 | PubMed |
| 2 | 18521084 | E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines. | Oncogene | 2008 | https://conductscience.org/library/papers/18521084 | PubMed |
| 3 | 19151774 | The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. | Leukemia | 2009 | https://conductscience.org/library/papers/19151774 | PubMed |
| 4 | 18641120 | Loss of p53 synthesis in zebrafish tumors with ribosomal protein gene mutations. | Proc Natl Acad Sci U S A | 2008 | https://conductscience.org/library/papers/18641120 | PubMed |
| 5 | 17971485 | Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lymphocytic leukemia. | Blood | 2008 | https://conductscience.org/library/papers/17971485 | PubMed |
| 6 | 17965322 | Prognostic relevance of FLT3-TKD mutations in AML: the combination matters--an analysis of 3082 patients. | Blood | 2008 | https://conductscience.org/library/papers/17965322 | PubMed |
| 7 | 18765522 | Targeting the MDM2-p53 interaction for cancer therapy. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18765522 | PubMed |
| 8 | 9153396 | Regulation of p53 stability by Mdm2. | Nature | 1997 | https://conductscience.org/library/papers/9153396 | PubMed |
| 9 | 16905541 | MDMX overexpression prevents p53 activation by the MDM2 inhibitor Nutlin. | J Biol Chem | 2006 | https://conductscience.org/library/papers/16905541 | PubMed |
| 10 | 12654245 | Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. | Cell | 2003 | https://conductscience.org/library/papers/12654245 | PubMed |
| 11 | 16213212 | Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. | Cell | 2005 | https://conductscience.org/library/papers/16213212 | PubMed |
| 12 | 16946709 | The tumor suppressor protein p53 is required for neurite outgrowth and axon regeneration. | EMBO J | 2006 | https://conductscience.org/library/papers/16946709 | PubMed |
| 13 | 11369655 | FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia. | Blood | 2001 | https://conductscience.org/library/papers/11369655 | PubMed |
| 14 | 16014563 | MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy. | Blood | 2005 | https://conductscience.org/library/papers/16014563 | PubMed |
| 15 | 19411846 | The transcription-independent mitochondrial p53 program is a major contributor to nutlin-induced apoptosis in tumor cells. | Cell Cycle | 2009 | https://conductscience.org/library/papers/19411846 | PubMed |
| 16 | 19776744 | The first 30 years of p53: growing ever more complex. | Nat Rev Cancer | 2009 | https://conductscience.org/library/papers/19776744 | PubMed |
| 17 | 16492744 | Mdm4 and Mdm2 cooperate to inhibit p53 activity in proliferating and quiescent cells in vivo. | Proc Natl Acad Sci U S A | 2006 | https://conductscience.org/library/papers/16492744 | PubMed |
| 18 | 18548093 | The dual PI3 kinase/mTOR inhibitor PI-103 prevents p53 induction by Mdm2 inhibition but enhances p53-mediated mitochondrial apoptosis in p53 wild-type AML. | Leukemia | 2008 | https://conductscience.org/library/papers/18548093 | PubMed |
| 19 | 19946262 | Selective FLT3 inhibitor FI-700 neutralizes Mcl-1 and enhances p53-mediated apoptosis in AML cells with activating mutations of FLT3 through Mcl-1/Noxa axis. | Leukemia | 2010 | https://conductscience.org/library/papers/19946262 | PubMed |
| 20 | 16439685 | MDM2 antagonists activate p53 and synergize with genotoxic drugs in B-cell chronic lymphocytic leukemia cells. | Blood | 2006 | https://conductscience.org/library/papers/16439685 | PubMed |
Cited by59
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 75 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41592087 | Patients with AML with WT TP53 but defective TP53-mediated apoptosis have a dismal survival. | JCI Insight | 2026 | https://conductscience.org/library/papers/41592087 | PubMed |
| 39223295 | Star wars against leukemia: attacking the clones. | Leukemia | 2024 | https://conductscience.org/library/papers/39223295 | PubMed |
| 39030997 | Phase 1 dose escalation study of the MDM2 inhibitor milademetan as monotherapy and in combination with azacitidine in patients with myeloid malignancies. | Cancer Med | 2024 | https://conductscience.org/library/papers/39030997 | PubMed |
| 37951964 | Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy. | Mol Cancer | 2023 | https://conductscience.org/library/papers/37951964 | PubMed |
| 37818252 | Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens. | Saudi Pharm J | 2023 | https://conductscience.org/library/papers/37818252 | PubMed |
| 37156796 | Optimized spirooxindole-pyrazole hybrids targeting the p53-MDM2 interplay induce apoptosis and synergize with doxorubicin in A549 cells. | Sci Rep | 2023 | https://conductscience.org/library/papers/37156796 | PubMed |
| 35141508 | Mechanical phenotyping reveals unique biomechanical responses in retinoic acid-resistant acute promyelocytic leukemia. | iScience | 2022 | https://conductscience.org/library/papers/35141508 | PubMed |
| 34970530 | Design, Synthesis, Chemical and Biochemical Insights Into Novel Hybrid Spirooxindole-Based p53-MDM2 Inhibitors With Potential Bcl2 Signaling Attenuation. | Front Chem | 2021 | https://conductscience.org/library/papers/34970530 | PubMed |
| 34911439 | Resistance mechanisms to inhibitors of p53-MDM2 interactions in cancer therapy: can we overcome them? | Cell Mol Biol Lett | 2021 | https://conductscience.org/library/papers/34911439 | PubMed |
| 32319019 | Targeting Apoptosis in Acute Myeloid Leukemia: Current Status and Future Directions of BCL-2 Inhibition with Venetoclax and Beyond. | Target Oncol | 2020 | https://conductscience.org/library/papers/32319019 | PubMed |
| 31717784 | Targeting Apoptotic Pathways in Acute Myeloid Leukaemia. | Cancers (Basel) | 2019 | https://conductscience.org/library/papers/31717784 | PubMed |
| 31653912 | Antitumor immunity augments the therapeutic effects of p53 activation on acute myeloid leukemia. | Nat Commun | 2019 | https://conductscience.org/library/papers/31653912 | PubMed |
| 31649884 | Targeting the GFI1/1B-CoREST Complex in Acute Myeloid Leukemia. | Front Oncol | 2019 | https://conductscience.org/library/papers/31649884 | PubMed |
| 31289443 | MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388). | Onco Targets Ther | 2019 | https://conductscience.org/library/papers/31289443 | PubMed |
| 30115703 | Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy. | Cancer Discov | 2018 | https://conductscience.org/library/papers/30115703 | PubMed |
| 29976747 | MDM2- and FLT3-inhibitors in the treatment of FLT3-ITD acute myeloid leukemia, specificity and efficacy of NVP-HDM201 and midostaurin. | Haematologica | 2018 | https://conductscience.org/library/papers/29976747 | PubMed |
| 29857559 | The Cellular p53 Inhibitor MDM2 and the Growth Factor Receptor FLT3 as Biomarkers for Treatment Responses to the MDM2-Inhibitor Idasanutlin and the MEK1 Inhibitor Cobimetinib in Acute Myeloid Leukemia. | Cancers (Basel) | 2018 | https://conductscience.org/library/papers/29857559 | PubMed |
| 29571049 | Lanthanide-doped nanoparticles conjugated with an anti-CD33 antibody and a p53-activating peptide for acute myeloid leukemia therapy. | Biomaterials | 2018 | https://conductscience.org/library/papers/29571049 | PubMed |
| 29490944 | Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. | Cancer Res | 2018 | https://conductscience.org/library/papers/29490944 | PubMed |
| 29343974 | Identification of key pathways and genes in TP53 mutation acute myeloid leukemia: evidence from bioinformatics analysis. | Onco Targets Ther | 2018 | https://conductscience.org/library/papers/29343974 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 | NCBI Gene |
| MDM2 | 4193 | PubTator's text mining | https://conductscience.org/library/genes/4193 | NCBI Gene |
| MDM4 | 4194 | PubTator's text mining | https://conductscience.org/library/genes/4194 | NCBI Gene |
| TP53 | 7157 | PubTator's text mining | https://conductscience.org/library/genes/7157 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/20404136
GET https://conductscience.org/api/papers/v1/20404136/references?page=2